Literature DB >> 3082644

The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects.

H V Curran, M Lader.   

Abstract

The psychopharmacological effects of fluvoxamine, 50 mg twice a day, were compared with those of mianserin, 20 mg twice a day, and placebo, each given for 8 days in a double-blind crossover design to 9 healthy human volunteers. At least one week was left between the 8-day courses of drugs. Testing was carried out before and 3 h after taking the morning dose on Days 1 (pre-drug), 4, and 8, and comprised EEG, cognitive and psychomotor tasks, and self-ratings of mood and bodily symptoms. Fluvoxamine had no effect on any of the EEG wavebands, but mianserin increased voltages in the slow wavebands as compared with placebo. This effect was particularly pronounced on Days 4 and 8. Mianserin significantly decreased critical flicker fusion frequency and speed of reaction time, and slowed down tapping rate; digit symbol substitution and symbol copying test performances were also impaired by mianserin. These effects were most marked after the first dose and had lessened somewhat later in the week. Symbol copying was the only task impaired by fluvoxamine as compared with placebo. Mianserin caused drowsiness after the first dose but this effect declined by Day 8. By contrast, fluvoxamine induced feelings of anxiety, sweatiness, trembling, nausea, loss of appetite, restlessness, muscle tension, irritability, tiredness, headache, and dizziness; these effects were most evident in the middle of the week and relatively reduced at the end of the week. Mianserin produced a few of these effects but they tended to be maximal on Day 1 or 4 and then to wear off.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082644     DOI: 10.1007/bf00635900

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Physiological and psychological effects of clorazepate in man.

Authors:  M H Lader; S Curry; W J Baker
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

2.  Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  V Claassen; J E Davies; G Hertting; P Placheta
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

3.  A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers.

Authors:  W H Wilson; H Higano; Y Papadatos; S Kelwala; T A Ban
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

4.  "Serotonin depression"--a biochemical subgroup within the affective disorders?

Authors:  M Asberg; P Thorén; L Träskman; L Bertilsson; V Ringberger
Journal:  Science       Date:  1976-02-06       Impact factor: 47.728

5.  Fluvoxamine-a new serotonin re-uptake inhibitor: first clinical and psychometric experiences in depressed patients.

Authors:  B Saletu; M Schjerve; J Grünberger; H Schanda; O H Arnold
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

6.  Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine.

Authors:  B Saletu; J Grünberger; P Rajna
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

7.  A double-blind controlled clinical trial comparing fluvoxamine with imipramine.

Authors:  J D Guelfi; J F Dreyfus; P Pichot
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

8.  A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression.

Authors:  T M Itil; R K Shrivastava; S Mukherjee; B S Coleman; S T Michael
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

  8 in total
  10 in total

Review 1.  Fluvoxamine: clinical trials and clinical use.

Authors:  C P Freeman
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

2.  Effects of repeated doses of fluvoxamine, mianserin and placebo on memory and measures of sedation.

Authors:  H V Curran; P Shine; M Lader
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 3.  5-Hydroxytryptamine and the pathophysiology of migraine.

Authors:  P P Humphrey
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

Review 4.  Behavioural toxicity of medicinal drugs. Practical consequences, incidence, management and avoidance.

Authors:  J G Ramaekers
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

5.  EEG profile of litoxetine after single and repeated administration in healthy volunteers.

Authors:  A Patat; S Trocherie; J J Thébault; P Rosenzweig; C Dubruc; G Bianchetti; P L Morselli; L A Court
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

6.  Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo.

Authors:  J G Ramaekers; H F Swijgman; J F O'Hanlon
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Interaction of alcohol with maprotiline or nomifensine: echocardiographic and psychometric effects.

Authors:  C Strömberg; A Suokas; T Seppälä
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 8.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Authors:  M I Wilde; G L Plosker; P Benfield
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

9.  Antidepressants and human memory: an investigation of four drugs with different sedative and anticholinergic profiles.

Authors:  H V Curran; M Sakulsriprong; M Lader
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  Study of the effect of nortriptyline and fluvoxamine on psychomotor functions in healthy volunteers.

Authors:  Ajay Khade; Mohammed Shakeel Mohamemed Bashir; A S Kale; Avinash Turankar
Journal:  Indian J Psychol Med       Date:  2010-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.